| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABCB1 |
| Uniprot No | P08183 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 350-710aa |
| 氨基酸序列 | PSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLFATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAGFDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRSSLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPY |
| 预测分子量 | 44.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABCB1重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Purification and reconstitution of human P-glycoprotein (ABCB1) in a functional state using a baculovirus expression system*"
**作者**：Seamus J. Allen 等
**摘要**：该研究利用杆状病毒-昆虫细胞系统成功表达并纯化了人源ABCB1重组蛋白。通过脂质体重构实验证实其具备ATP依赖的药物转运活性，为体外药物相互作用研究提供了可靠模型。
2. **文献名称**：*"Crystal structure of the multidrug transporter ABCB1 in complex with a cyclic inhibitor*"
**作者**：Aller, S.G. 等(Nature, 2009)
**摘要**：通过X射线晶体学解析了小鼠ABCB1重组蛋白与抑制剂的复合物结构，揭示了其底物结合腔的构象变化及ATP水解驱动药物外排的分子机制，为多药耐药性抑制剂设计奠定基础。
3. **文献名称**：*"ATPase activity of human ABCB1 (P-glycoprotein) is modulated by distinct regions of the nucleotide-binding domains*"
**作者**：Suresh V. Ambudkar 等
**摘要**：研究通过重组表达人ABCB1蛋白的核苷酸结合域(NBDs)突变体，阐明了NBDs中关键氨基酸对其ATP酶活性的调控作用，证实ATP水解与跨膜结构域构象偶联的分子机制。
---
**注**：以上文献为示例，实际引用时需核对作者、标题及发表年份的准确性。建议通过PubMed或Web of Science以关键词“ABCB1 recombinant protein”搜索最新研究。
ABCB1. also known as P-glycoprotein (P-gp) or multidrug resistance protein 1 (MDR1), is a member of the ATP-binding cassette (ABC) transporter superfamily. It is a transmembrane protein encoded by the ABCB1 gene in humans, primarily expressed in barrier and excretory tissues such as the intestine, liver, kidney, and blood-brain barrier. ABCB1 functions as an ATP-dependent efflux pump, actively transporting a wide range of structurally diverse endogenous and exogenous substrates out of cells, including chemotherapeutic agents, antibiotics, and toxins. This broad substrate specificity underpins its critical role in multidrug resistance (MDR) in cancer therapy, where overexpression of ABCB1 reduces intracellular drug accumulation, diminishing treatment efficacy.
Recombinant ABCB1 protein is produced using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to study its structure, function, and interactions. Its recombinant form retains the characteristic 170–180 kDa molecular weight and two homologous halves, each containing six transmembrane helices and a nucleotide-binding domain (NBD) for ATP hydrolysis. Researchers employ purified ABCB1 to investigate transport kinetics, inhibitor screening, and structural dynamics using techniques like cryo-EM, which has revealed conformational changes during ATP-driven substrate translocation.
Pharmaceutically, ABCB1 recombinant protein is pivotal in drug discovery to assess drug-drug interactions, blood-brain barrier penetration, and oral bioavailability. It also serves as a tool to develop modulators that overcome MDR or enhance therapeutic delivery. Despite challenges in maintaining native folding and post-translational modifications during recombinant production, advances in expression systems continue to improve its functional reliability for both basic research and translational applications.
×
